Clinical trials: Feasibility
Healthy Volunteers
Study to Compare Relative Bioavailability of 3 Indacaterol/Glycopyrronium Test Products and Reference Product
This is a formulation feasibility study to to compare relative bioavailability of indacaterol and glycopyrronium after administration of single doses of 3 Easyhaler test products and Ultibro Breezhaler.
- Trial name
- FORELLI (NCT05288075)
- Testing
- Indacaterol/glycopyrronium
- Where
- Finland
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Orion Corporation, Orion Pharma
Recurrent Glioblastoma
A Study of Intra-tumoral Administered MTX110 in Patients With Recurrent Glioblastoma
A study designed to assess the safety of MTX110 in patients suffering with recurrent glioblastoma. MTX110 will be administered directly to the site of the tumour via a catheter which is inserted during a surgical procedure at the…
- Trial name
- MAGIC-G1 (NCT05324501)
- Testing
- MTX110, Programmable pump and catheter system
- Where
- 2 sites in United States
- Volunteers
- 4 people
- Sponsor
- Biodexa Pharmaceuticals
Bacterial Vaginosis, Fungal Vaginal Infections
Clinical Protocol CERN Feasibility Study
The goal of this clinical trial is to learn if the intravaginal Cern device works to treat bacterial vaginosis and fungal vaginitis in premenopausal women. It will also learn about the safety of the device.
- Trial name
- NCT06933420
- Testing
- Cern Device
- Where
- 3 sites in United States
- Volunteers
- 9 people
- Sponsor
- Cern Corporation
Non Small Cell Lung Cancer, Pancreatic Cancer
Feasibility Study to Investigate Rectal Mucus in Aero-Digestive Tract Cancer.
The aim of the study is to assess the feasibility of genomic and epigenetic analysis of rectal mucus to detect non-colorectal cancers of the aero- digestive tract using samples collected by the OriCol™ Sampling Device.
- Conditions
- Non Small Cell Lung Cancer, Pancreatic Cancer, Bladder Cancer, Colorectal Cancer
- Trial name
- ORI-EGI-03 (NCT05102110)
- Testing
- Oricol Test
- Where
- United Kingdom
- Volunteers
- 450 people
- Sponsor
- Origin Sciences
Heart Failure With Preserved Ejection Fraction (HFpEF), Hypertension
Study for the Treatment of Heart Failure With Preserved Ejection Fraction Associated With High Blood Pressure Using Right Atrial Pacing Controlled by the PressurePaceTM System
This study is a prospective, double blind, self-controlled, randomized, cross-over study to evaluate the feasibility, efficacy, and safety of treating patients with Heart Failure with preserved Ejection Fraction (HFpEF)…
- Trial name
- RelieveHFpEFII (NCT06036186)
- Testing
- BaroPacing treatment, Standard treatment
- Where
- 3 sites in India
- Volunteers
- 16 people
- Sponsor
- BaroPace Inc.
Liver Cancer
Evaluation of a Minimally Invasive Image-Guided Surgery System for Hepatic Ablation Procedures
This study was designed in two phases: Phase I is designed to confirm that the surgeon is able to perform accurate liver surface registration including standard liver features used as landmarks during a scheduled laparoscopic…
- Trial name
- NCT01238666
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Pathfinder Therapeutics
Asthma
Integrated Digitally Enhanced Care for Long-term Conditions- Asthma
Asthma is a common lung condition that causes long term breathing difficulties. There is currently no cure for asthma but the use of simple inhaler treatments can keep the symptoms under control.
- Trial name
- IDEAL (NCT03511482)
- Testing
- myAsthma Application, Lloyds Pharmacy Online Doctor
- Where
- United Kingdom
- Sponsor
- my mhealth Ltd
Targeted Temperature Management
Feasibility Study for VCool™ Intranasal Cooling System in Healthy Volunteers
The objective of this study is to evaluate the performance and safety of the VCool Intranasal Cooling System in healthy adult volunteers.
- Trial name
- NCT07361588
- Testing
- Targeted Temperature Management Intranasal Cooling System
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- NeuroIntact Inc.
Cerebrovascular Disease
On-Premise and Remote Robotic Neurointervention
This study is a prospective, single arm, single-center study to evaluate the safety and feasibility of the Remedy Robot for on premise and remote robotic Neurointervention.
- Trial name
- NCT06365554
- Testing
- Remedy Robot
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Remedy Robotics, Inc.
Breast Cancer, Breast-conserving Surgery
Feasibility Study for the SIRA-1000, SIRA® RFA Electrosurgical Device as an Adjunct to Breast Conserving Surgery
This study aims to assess the safety and clinical accuracy of the SIRA-1000, SIRA® RFA Electrosurgical Device in ablating margins post-lumpectomy in patients undergoing breast conserving surgery for breast cancer.
- Conditions
- Breast Cancer, Breast-conserving Surgery, Breast Cancer - Infiltrating Ductal Carcinoma, ER/PR+Her2neu
- Trial name
- NCT07206121
- Testing
- Radiofrequency ablation alone, Radiofrequency ablation Electrosurgical Device
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Innoblative Designs, Inc.
Patients Who Were Scheduled for General and Gynecological Laparoscopic Procedures
Evaluation of the Follow Me Mode of the AutoLap System - A Feasibility Study
The main objectives of this study are to evaluate the performance and ease of use of the Follow me mode of the AutoLap system during general and gynecological laparoscopic procedures.
- Trial name
- NCT02326870
- Testing
- AutoLap
- Where
- 4 sites in Israel, Netherlands
- Volunteers
- 33 people
- Sponsor
- M.S.T. Medical Surgery Technology LTD.
Perineal Trauma
Ward-Level Implementation and Post-Market Clinical Follow-up Study of ASISU Under Routine Clinical Practice
This is a single-center, prospective, non-randomized post-market clinical follow-up study evaluating the implementation and clinical performance of ASISU during routine vaginal childbirth.
- Trial name
- ASISU-PMCF (NCT07844005)
- Testing
- Perineal protection device
- Where
- Denmark
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- oasicare ApS
Parkinson Disease
NeuroGlove PD Study Clinical
Safety and Feasibility of Peripheral Sensory Stimulation of the Hand in the Treatment of Parkinson's Disease
- Trial name
- NCT06578273
- Testing
- NeuroGlove
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- NeuroGlove LLC
Tricuspid Regurgitation
Feasibility Study of Dragonfly System for Severe Tricuspid Regurgitation
The study is designed to assess the feasibility of the DragonFly transcatheter mitral valve clamping system for the treatment of symptomatic severe tricuspid regurgitation.
- Trial name
- NCT04921605
- Testing
- DragonFly transcatheter mitral valve clamping system
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Hangzhou Valgen Medtech Co., Ltd
Reduction of Postoperative Adhesions
Evaluation of the Feasibility, Safety, Initial Efficacy and Clinical Usability of FuseX Anti-Adhesion System
Evaluation of the feasibility, safety, initial efficacy and usability of FuseX Anti-Adhesion system toward further studies that will be powered to proved its safety and efficacy.
- Trial name
- NCT03820713
- Testing
- Concentrate of plasma coagulation factors, 0.9% saline
- Where
- 2 sites in Lithuania
- Volunteers
- 30 people
- Sponsor
- Eio Biomedical Ltd.
Asthma
A 12-Week Treatment Study to Evaluate the Effectiveness of Albuterol Multidose Dry Powder Inhaler With Integrated Electronic Module Digital System (eMDPI DS) in Participants13 Years or Older With Asthma
This is a 12-week treatment, multicenter, open-label, randomized, parallel group comparison feasibility study to evaluate the effectiveness of the Albuterol eMDPI Digital System (DS), including inhaler, App, digital health…
- Trial name
- CONNECT1 (NCT03890666)
- Testing
- Albuterol eMDPI DS, albuterol
- Where
- 29 sites in United States
- Volunteers
- 333 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Pancreatic Adenocarcinoma
Safety Feasibility and Effect of TTFields (150 kHz) Concomitant With Gemcitabine or Concomitant With Gemcitabine Plus Nab-paclitaxel for Front-line Therapy of Advanced Pancreatic Adenocarcinoma (PANOVA)
The study is a prospective, double arm, non-randomized, open label pilot trial, designed to study the safety, feasibility and preliminary efficacy of a medical device, the NovoTTF-100L concomitant with gemcitabine or concomitant…
- Trial name
- NCT01971281
- Testing
- NovoTTF-100L, Gemcitabine, nab-Paclitaxel
- Where
- 6 sites in Spain, Switzerland
- Volunteers
- 40 people
- Sponsor
- NovoCure Ltd.
Major Depressive Disorder
Safety and Feasibility of Combined Trigeminal and Occipital Transcutaneous Nerve Stimulation (CTO-TNS) in Major Depressive Disorder (MDD)
Safety and Feasibility of Combined Trigeminal and Occipital Transcutaneous Nerve Stimulation (CTO-TNS) in Major Depressive Disorder (MDD)
- Trial name
- CTO-TNS (NCT02805881)
- Testing
- Neurolief system
- Where
- Israel
- Volunteers
- 28 people
- Sponsor
- Neurolief Ltd.
Cognitive Impairment, Mild
Telerehabilitation Cognitive Impairments Following Chemotherapy Feasibility Study
Develop a game-based upper-extremity motor and cognitive rehabilitation system using custom and adaptable virtual reality simulations on a wearable device enhanced with biosensors.
- Trial name
- TCIFCF (NCT04972019)
- Testing
- Telerehabilitation Experimental Group
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Bright Cloud International Corp
Head and Neck Cancer, Cervical Cancer
A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors
TScan Therapeutics is developing cellular therapies across multiple solid tumors in which autologous participant-derived engeneered T cells are engineered to express a T cell receptor that recognizes cancer-associated antigens…
- Conditions
- Head and Neck Cancer, Cervical Cancer, Non-small Cell Carcinoma, Melanoma
- Trial name
- NCT05973487
- Testing
- TSC-204-A0201, TSC-204-C0702, TSC-200-A0201
- Where
- 21 sites in United States
- Volunteers
- 840 people
- Sponsor
- TScan Therapeutics, Inc.